Acute liver failure is a complex and fatal disease. Cell-based therapies are a promising alternative therapeutic approach for liver\nfailure due to relatively simple technique and lower cost. The use of semipermeable microcapsules has become an interesting tool\nfor evaluating paracrine effects in vivo. In this study, we aimed to assess the paracrine effects of bone marrow mononuclear cells\n(BMMC) encapsulated in sodium alginate to treat acute liver failure in an animal model of 90% partial hepatectomy (90% PH).\nEncapsulated BMMC were able to increase 10-day survival without enhancing liver regeneration markers. Gene expression of Il-6\nand Il-10 in the remnant liver was markedly reduced at 6 h after 90% PH in animals receiving encapsulated BMMC compared to\ncontrols. This difference, however, was neither reflected by changes in the number of CD68+ cells nor by serum levels of IL6. On\nthe other hand, treated animals presented increased caspase activity and gene expression in the liver. Taken together, these results\nsuggest that BMMCregulate immune response and promote apoptosis in the liver after 90%PHby paracrine factors. These changes\nultimately may be related to the higher survival observed in treated animals, suggesting thatBMMCmay be a promising alternative\nto treat acute liver failure.
Loading....